Yayınlar & Eserler

Yayın Ağı
Makaleler 45
Tümü (45)
SCI-E, SSCI, AHCI (41)
SCI-E, SSCI, AHCI, ESCI (42)
ESCI (1)
Scopus (42)
TRDizin (3)

1. Evaluation of the efficacy and tolerability of bevacizumab-based treatments in recurrent primary brain tumors: a multicenter real-world Turkish Oncology Group (TOG) study

Sucuoğlu İşleyen Z., Seçmeler Ş., Sakin A., Cihan Ş., Beşiroğlu M., Kahraman S., et al.
BMC Cancer , cilt.26, sa.1, 2026 (SCI-Expanded, Scopus) identifier identifier identifier

2. Clinical Significance of Achieving No Evidence of Disease in HER2-Positive Metastatic Breast Cancer: A Multicenter Study by Turkish Oncology Group (TOG)

Dursun B., YASLIKAYA Ş., Sekmek S., Önder T., Yıldırım H. Ç., Acar Ö., et al.
Cancers , cilt.18, sa.6, 2026 (SCI-Expanded, Scopus) identifier identifier identifier

3. Birinci basamakta hedefe yönelik ajanlarla tedavi edilen RAS mutasyonu taşımayan metastatik kolorektal kanser hastalarında gerçek yaşam verileri: Ulusal onco-colon Türkiye kayıt sistemi

TATLIDEDE D., Arslan C., YILDIRIM M. E., Işıkdoğan A., Karadurmuş N., Karabulut B., et al.
ANADOLU KLİNİĞİ TIP BİLİMLERİ DERGİSİ , cilt.31, sa.1, ss.42-51, 2026 (TRDizin) Creative Commons License identifier

4. Long-Term Oncological Outcomes for Locally Advanced Rectal Cancer Patients with Pathological Complete Response After Neoadjuvant Chemoradiotherapy: A Turkish Oncology Group Study

Uysal M., Saglam S., Beypınar İ., Saglam E. K., Mammadov E., Ocak B., et al.
Cancer Investigation , cilt.44, sa.2, ss.127-135, 2026 (SCI-Expanded, Scopus) identifier identifier identifier

5. Real-World Survival Outcomes Following Metastasectomy in RAS Wild-Type mCRC: Insights from a Multicentre National Cohort Study

Okten I. N., Baydas T., Yildirim M. E., Bilir C., YALÇIN Ş., ÇUBUKÇU E., et al.
JOURNAL OF CLINICAL MEDICINE , cilt.15, sa.2, 2026 (SCI-Expanded, Scopus) identifier identifier

6. Talazoparib in patients with BRCA mutant metastatic breast or ovarian carcinoma: results of early access program

ŞENDUR M. A. N., Hizal M., Cakar B., AKTEPE O. H., Eraslan E., ARIK Z., et al.
BMC CANCER , cilt.25, sa.1, 2025 (SCI-Expanded, Scopus) identifier identifier identifier

7. Factors Affecting the Survival of Metastatic Breast Cancer Patients Treated with CDK 4/6 Inhibitors

Sucuoğlu İşleyen Z., MUĞLU H., Alaca Topçu Z., Beşiroğlu M., Yasin A. İ., Topçu A., et al.
Medicina (Lithuania) , cilt.61, sa.7, 2025 (SCI-Expanded, Scopus) identifier identifier identifier

8. Cemiplimab monotherapy as first-line treatment of patients with brain metastases from advanced non–small cell lung cancer with programmed cell death-ligand 1 ≥50%

Kilickap S., ÖZGÜROĞLU M., Sezer A., Gümüş M., Bondarenko I., Gogishvili M., et al.
Cancer , cilt.131, sa.10, 2025 (SCI-Expanded, Scopus) identifier identifier

9. Long-Term Outcomes of Patients Undergoing Conversion Surgery After Induction Chemotherapy: Turkish Oncology Group Study

Ceylan F., Aktürk Esen S., Ünal O. Ü., Aslan F., Onur İ. D., Ateş Ö., et al.
Medicina (Lithuania) , cilt.61, sa.5, 2025 (SCI-Expanded, Scopus) identifier identifier identifier

10. Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC

Yildirim M. E., Karadurmus N., Okten I. N., TÜRK H. M., Urakci Z., Arslan C., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.31, sa.3, ss.404-411, 2025 (SCI-Expanded, Scopus) identifier identifier identifier

11. Assessing the Efficacy and Safety of Shorter versus Extended Adjuvant Treatment Duration for Stage III Low-Risk Colon Cancer: A Comparative Analysis

Kalkan N., Ucar G., Esen S., Bardakci M., Aydin S., Celebi A., et al.
NIGERIAN JOURNAL OF CLINICAL PRACTICE , cilt.28, sa.2, ss.212-218, 2025 (SCI-Expanded, Scopus) identifier identifier identifier

12. New targets and strategies in treatment of metastatic gastric cancer

Simsek M., TÜRK H. M.
Future Oncology , cilt.21, sa.22, ss.2931-2940, 2025 (SCI-Expanded, Scopus) identifier

13. Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases

Kahraman S., Karakaya S., Kaplan M. A., SEZGİN GÖKSU S., Ozturk A., Isleyen Z. S., et al.
Scientific Reports , cilt.14, sa.1, 2024 (SCI-Expanded, Scopus) identifier identifier identifier

14. Assessment of cyclin D1 activity in tumors and tumor budding and its prognostic significance in tumor budding in colorectal carcinomas.

Coban G., Arici D. S., Tekden B. C., Yildiz P., Kiran T., Toluk Ö., et al.
Indian journal of pathology & microbiology , cilt.67, sa.4, ss.753-757, 2024 (SCI-Expanded, Scopus) identifier identifier identifier

15. Cardiac safety of ribociclib evaluated with 24-hour rhythm Holter electrocardiogram

Yasin A. I., ULUGANYAN M., Isleyen Z. S., Topcu A., Shbair A. T., ŞİMŞEK M., et al.
Supportive Care in Cancer , cilt.32, sa.8, 2024 (SCI-Expanded, Scopus) identifier identifier

16. Pretreatment HALP Score Predicts Prognosis in Patients with Esophageal Cancer Treated with Chemoradiotherapy

İŞLEYEN Z. S., BEŞİROĞLU M., ŞİMŞEK M., YASİN A. İ., TOPÇU A., AKÇAKAYA A., et al.
Eurasian Journal of Medical Investigation , cilt.8, sa.2, ss.113-118, 2024 (TRDizin) identifier

17. A propensity score-matched comparison of neoadjuvant chemoradiotherapy with cisplatin-5FU and carboplatin–paclitaxel in locally advanced esophageal squamous cell carcinoma: A Turkish oncology group study

GÜRLER F., Tay F., Sucuoğlu İşleyen Z., Yerlikaya T., Hendem E., Esen S. A., et al.
Cancer Medicine , cilt.13, sa.14, 2024 (SCI-Expanded, Scopus) identifier identifier

18. Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial.

Wainberg Z. A., Kang Y., Lee K., Qin S., Yamaguchi K., Kim I., et al.
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association , cilt.27, sa.3, ss.558-570, 2024 (SCI-Expanded, Scopus) identifier identifier identifier

19. Promising outcome of patients with recurrent glioblastoma after Gamma Knife-based hypofractionated radiotherapy

HATİBOĞLU M. A., Akdur K., Sakarcan A., SEYİTHANOĞLU M. H., TÜRK H. M., Sinclair G., et al.
Neurochirurgie , cilt.70, sa.2, 2024 (SCI-Expanded, Scopus) identifier identifier identifier

20. Prevalence and co-incidence of geriatric syndromes according to the ECOG performance status in older cancer patients.

Topcu A., Yasin A. I., Besiroglu M., Sucuoglu Isleyen Z., Alaca Topcu Z., Simsek M., et al.
Frontiers in medicine , cilt.11, ss.1331246, 2024 (SCI-Expanded, Scopus) Creative Commons License identifier identifier identifier

21. Local interventions for colorectal cancer metastases to liver and lung

ŞİMŞEK M., Besiroglu M., AKÇAKAYA A., Topcu A., Yasin A. I., Isleyen Z. S., et al.
Irish Journal of Medical Science , cilt.192, sa.6, ss.2635-2641, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

22. The risk of malnutrition and its clinical implications in older patients with cancer.

Sucuoglu Isleyen Z., Besiroglu M., Yasin A. I., Simsek M., Topcu A., Smith L., et al.
Aging clinical and experimental research , cilt.35, sa.11, ss.2675-2683, 2023 (SCI-Expanded, Scopus) identifier identifier identifier

23. Differentiation of lung and breast cancer brain metastases: Comparison of texture analysis and deep convolutional neural networks

Gultekin M. A., Peker A. A., Oktay A. B., Turk H. M., Cesme D. H., Shbair A. T. M., et al.
JOURNAL OF CLINICAL ULTRASOUND , cilt.51, sa.9, ss.1579-1586, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

24. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial

Shah M. A., Shitara K., Ajani J. A., Bang Y., Enzinger P., Ilson D., et al.
Nature Medicine , cilt.29, sa.8, ss.2133-2141, 2023 (SCI-Expanded, Scopus) Creative Commons License identifier identifier identifier

25. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.

Tsuboi M., Herbst R. S., John T., Kato T., Majem M., Grohé C., et al.
The New England journal of medicine , cilt.389, sa.2, ss.137-147, 2023 (SCI-Expanded, Scopus) identifier identifier identifier

26. Comparison of different decision support software programs in perspective of potential drug-drug interactions in the oncology clinic

Bektay M. Y., Şeker Z., Eke H. K., Türk H. M., İzzettin F. V.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.29, sa.5, ss.1178-1186, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

27. Stem cell markers: A guide to neoadjuvant therapy inbreast carcinomas

Gücin Z., Büyükpınarbaşılı N., Geçer M., Ersoy Y. E., Türk H. M., Yıldız Ş., et al.
INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY , cilt.66, ss.495-501, 2023 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

28. The correlation between skeletal muscle index and anxiety in patients with lung cancer on the first day of chemotherapy.

Topcu A., Yurtsever İ., Isleyen Z. S., Besiroglu M., Yasin A. I., Topcu Z. A., et al.
Future oncology (London, England) , cilt.19, sa.16, ss.1139-1149, 2023 (SCI-Expanded, Scopus) identifier identifier identifier

29. The prognostic value of tumor budding in gastric adenocarcinomas: A cross-sectional study

Baydas T., ÇOBAN G., Besiroglu M., ŞİMŞEK M., Shbair A. T., Topcu A., et al.
International Journal of Gastrointestinal Intervention , cilt.12, sa.2, ss.69-74, 2023 (ESCI, Scopus) Sürdürülebilir Kalkınma identifier identifier

30. Second-line Therapy after Trastuzumab Failure in HER2- Positive Metastatic Gastric Cancer: A Real-life Data

Topçu A., Beşiroğlu M., Atçı M. M., Secmeler Ş., Ayhan M., Özkan M., et al.
Eurasian Journal of Medical Investigation , cilt.7, sa.2, ss.153-161, 2023 (TRDizin) Sürdürülebilir Kalkınma

31. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study.

Wainberg Z. A., Enzinger P. C., Kang Y., Qin S., Yamaguchi K., Kim I., et al.
The Lancet. Oncology , cilt.23, ss.1430-1440, 2022 (SCI-Expanded, Scopus) identifier identifier identifier identifier

32. The effect of sarcopenia on erlotinib therapy in patients with metastatic lung adenocarcinoma.

Topcu A., Ozturk A., Yurtsever İ., Besiroglu M., Yasin A. I., Turk H. M., et al.
Bosnian journal of basic medical sciences , cilt.22, sa.6, ss.982-991, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

33. The efficacy of BNT162b2 (Pfizer-BioNTech) and CoronaVac vaccines in patients with cancer

ŞİMŞEK M., Yasin A., BEŞİROĞLU M., TOPÇU A., SUCUOĞLU İŞLEYEN Z., ŞEKER M., et al.
JOURNAL OF MEDICAL VIROLOGY , cilt.94, sa.9, ss.4138-4143, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

34. Breast Cancer Patients with Brain Metastases: A Cross-Sectional Study.

Simsek M., Aliyev A., Baydas T., Besiroglu M., Demir T., Shbair A. T., et al.
The breast journal , cilt.2022, ss.5763810, 2022 (SCI-Expanded, Scopus) Creative Commons License identifier identifier identifier

35. Diffusion Tensor Imaging Can Discriminate the Primary Cell Type of Intracranial Metastases for Patients with Lung Cancer.

Bilgin S. S., Gultekin M. A., Yurtsever İ., Yilmaz T. F., Cesme D. H., Bilgin M., et al.
Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine , cilt.21, sa.3, ss.425-431, 2022 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

36. Evaluation of toxic effects of chemotherapy in lung malignancies on cerebral white matter using diffusion tensor imaging

Aydin S., Demir T., Turk H. M., Cesme D. H., Aliyev A., Ali Gultekin M. A., et al.
RADIOLOGY AND ONCOLOGY , cilt.56, sa.2, ss.150-155, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

37. Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study

YASİN A. İ., Aydin S. G., SÜMBÜL B., KORAL L., ŞİMŞEK M., Geredeli C., et al.
FUTURE ONCOLOGY , cilt.18, ss.1235-1244, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

38. A case report of fulminant hepatitis due to ribociclib with confirmed by liver biopsy in breast cancer

TOPÇU A., YASİN A. İ., SHBAIR A. T., BEŞİROĞLU M., ŞİMŞEK M., SUCUOĞLU İŞLEYEN Z., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.28, sa.1, ss.242-246, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

39. First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer

Esen S. A., Ergun Y., Erol C., Arikan R., Er M. M., Atci M. M., et al.
Bosnian Journal of Basic Medical Sciences , cilt.22, sa.5, ss.818-825, 2022 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

40. Diagnostic performance of apparent diffusion coefficient values for the differentiation of intrahepatic cholangiocarcinoma from gastrointestinal adenocarcinoma liver metastases.

Yilmaz T. F., Gultekin M. A., Turk H. M., Besiroglu M., Cesme D. H., Simsek M., et al.
Radiology and oncology , cilt.56, sa.1, ss.54-59, 2021 (SCI-Expanded, Scopus) Creative Commons License identifier identifier identifier

41. A comparison of anticholinergic burden in older patients with and without cancer.

Yasin A. I., Topcu A., Akuc M. N., Türk H. M., Soysal P.
Future oncology (London, England) , cilt.17, sa.36, ss.5067-5075, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

42. Successful retreatment with erlotinib after erlotinib-related interstitial lung disease.

Turk H. M., Adli M., Simsek M., Aliyev A., Besiroglu M.
Tumori , cilt.107, sa.6, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

43. Primitive Neuroectodermal Tumor of the Testis

DEMİR T., ALİYEV A., ŞEKER M., ERSÖZ C., ÇOBAN G., TÜRK H. M.
JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN , cilt.31, sa.11, ss.1362-1365, 2021 (SCI-Expanded, Scopus) Creative Commons License identifier identifier identifier

44. Apparent Diffusion Coefficient Values for Neuroendocrine Liver Metastases.

Gultekin M. A., Turk H. M., Yurtsever İ., Cesme D. H., Seker M., Besiroglu M., et al.
Academic radiology , cilt.28, 2021 (SCI-Expanded, Scopus) identifier identifier identifier

45. Anxiety levels of breast cancer patients in Turkey during the COVID-19 pandemic

YASİN A. İ., TOPÇU A., SHBAIR A. T., SUCUOĞLU İŞLEYEN Z., ÖZTÜRK A., BEŞİROĞLU M., et al.
FUTURE ONCOLOGY , cilt.17, ss.3373-3381, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 3

1. The frequency of driver mutations in non-small cell lung cancer patients: The Turkish nation-wide, observational, Registurk-Lung study (updated analysis).

Turan N., Cil T., Artac M., Hacibekiroglu I., Sumbul A. T., Uncu D., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2025, cilt.43, (Özet Bildiri) identifier identifier

2. Comparison of different decision support software programs in perspective of potential drug-drug interactions in oncology clinic.

Bektay M. Y., Şeker Z., Eke H. K., Türk H. M., İzzettin F. V.
48TH SYMPOSIUM OF EUROPEAN SOCIETY OF CLINICAL PHARMACY (ESCP), Ljubljana, Slovenya, 22 Ekim 2019, cilt.42, ss.229, (Özet Bildiri)

3. Meme karsinomunda ''stem hücre'' belirteçleri neoadjuvan tedavide yol gösterici olabilir mi?

GÜCİN Z., BÜYÜKPINARBAŞILI N., ÖZGÜN GEÇER M., ERSOY Y. E., CENGİZ M. B., TÜRK H. M., et al.
28. Ulusal Patoloji Kongresi, Ankara, Türkiye, 27 - 30 Ekim 2018, (Özet Bildiri)
Metrikler

Yayın

131

Yayın (WoS)

110

Yayın (Scopus)

102

Atıf (WoS)

2693

H-İndeks (WoS)

18

Atıf (Scopus)

2850

H-İndeks (Scopus)

17

Atıf (Scholar)

3

H-İndeks (Scholar)

1

Proje

3

Tez Danışmanlığı

2

Açık Erişim

24
BM Sürdürülebilir Kalkınma Amaçları